Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.43 |
| ▸ | CRHR1 | P34998 | 14/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20115352 | 0.86 | TLR7 (0.37) | MAP3K12CRHR1MEN1KMT2ATLR8 | |
| SCHEMBL9747604 | 0.72 | CRHR1 (0.49) | CRHR1LMNAAGTR1MAPK8AGTR2 | |
| SCHEMBL19273533 | 0.70 | MAP3K12 (0.36) | MAP3K12 | |
| SCHEMBL21695286 | 0.69 | MAP3K12 (0.41) | MAP3K12 | |
| SCHEMBL12871103 | 0.69 | TDP1 (0.44) | CRHR1LMNA | |
| SCHEMBL20115463 | 0.68 | MAP3K12 (0.38) | MAP3K12 | |
| SCHEMBL19273502 | 0.66 | MAP3K12 (0.32) | MAP3K12 | |
| SCHEMBL8156919 | 0.65 | LMNA (0.49) | CRHR1LMNAAGTR1MAPK8AGTR2 | |
| SCHEMBL821901 | 0.65 | CRHR1 (0.67) | CRHR1 | |
| SCHEMBL6691989 | 0.65 | MAPT (0.44) | CRHR1LMNAMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133219-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133219-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | BCHE, SNCA, HAX1 | MAP3K12 1980/4885CRHR1 114/4885LMNA 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.